bivalent covid-19 mrna booster vaccination  (Pfizer Inc)

Journal: Vaccine

Article Title: Development of COVID-19 vaccine policy — United States, 2020–2023 ☆

doi: 10.1016/j.vaccine.2023.12.022

Figure Lengend Snippet: Timeline of COVID-19 vaccine policy decisions.

Article Snippet: While details of the data reviewed are provided elsewhere[ ], after reviewing the totality of available data, ACIP recommended bivalent mRNA booster vaccines for persons ages ≥ 12 years (Pfizer-BioNTech) and adults ages ≥ 18 years (Moderna)[ ].

Techniques: Vaccines, Transmission Assay

Journal: The Journal of Clinical Investigation

Article Title: Randomized controlled trial reveals no benefit to a 3-month delay in COVID-19 mRNA booster vaccine

doi: 10.1172/JCI181244

Figure Lengend Snippet: Plasma neutralizing activity was measured using a live virus neutralization assay against SARS-CoV-2 Omicron BA.1 ( A – E ) and XBB.1.5 ( F – J ) variants. Pre-booster ( A and F ) and post-booster day-14 (D14) ( D and I ) and day-84 (D84) ( E and J ) neutralizing antibody responses were compared between the delayed (blue/purple diamonds, n = 24) and immediate arms (pink triangles, n = 24) at the respective sampling time points. Line graphs describe the kinetics of plasma neutralization activity of the delayed ( B and G ) and immediate ( C and H ) arms after receiving the bivalent booster. Numbers above each time point describe the respective median neutralization IC 50 against each viral variant. Dotted lines depict the detection threshold for the assay (neutralization IC 50 = 20). Dark purple diamonds and lines show the antibody responses of the 3 individuals who received the BA.5 bivalent booster in the delayed arm of the study. Saliva neutralizing activity against ancestral SARS-CoV-2 was measured using the sVNT (Genscript). Pre-booster ( K ) and post-booster day-14 ( N ) neutralizing antibody responses were compared between the delayed (purple diamonds, n = 18) and immediate arms (pink triangles, n = 19), respectively. Line graphs describe the change in saliva neutralization activity following the bivalent booster ( L and M ). Numbers describe the percentage of surrogate neutralization observed at each time point. Dotted lines depict the sVNT cutoff for neutralizing activity (30%). Statistical significance was calculated between cohorts and time points using the 2-tailed Mann-Whitney U test or the Kruskal-Wallis test followed by Dunn’s multiple-comparison test. Paired saliva analysis (day 0 vs. day 14) was performed using the Wilcoxon matched-pairs, signed-rank test. Experiments were performed in duplicate. Graphs are displayed as the median, and where significant, P values are reported (** P ≤ 0.01, *** P ≤ 0.001, and **** P ≤ 0.0001).

Article Snippet: Participants were recruited in Melbourne, Australia, and were randomized to receive a Moderna BA.1 bivalent mRNA vaccine booster dose (0.5 mL) administered intramuscularly upon enrollment (immediate arm) or 3 months later (delayed arm).

Techniques: Activity Assay, Virus, Neutralization, Sampling, Variant Assay, MANN-WHITNEY, Comparison